CLINICAL TRIALS PROFILE FOR ACETAZOLAMIDE

All Clinical Trials for ACETAZOLAMIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000115 ↗	Randomized Trial of Acetazolamide for Uveitis-Associated Cystoid Macular Edema	Completed	National Eye Institute (NEI)	Phase 2	1990-12-01	To test the efficacy of acetazolamide for the treatment of uveitis-associated cystoid macular edema.
NCT00004802 ↗	Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dichlorphenamide for Periodic Paralyses and Associated Sodium Channel Disorders	Completed	Ohio State University	Phase 3	1992-06-01	OBJECTIVES: I. Assess the efficacy of dichlorphenamide in the treatment of episodic weakness attacks in patients with hyperkalemic periodic paralysis, paramyotonia congenita with periodic paralysis, and hypokalemic periodic paralysis.
NCT00004802 ↗	Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dichlorphenamide for Periodic Paralyses and Associated Sodium Channel Disorders	Completed	National Center for Research Resources (NCRR)	Phase 3	1992-06-01	OBJECTIVES: I. Assess the efficacy of dichlorphenamide in the treatment of episodic weakness attacks in patients with hyperkalemic periodic paralysis, paramyotonia congenita with periodic paralysis, and hypokalemic periodic paralysis.
NCT00108602 ↗	Sleep Apnea: Mechanism and Cerebrovascular Consequences	Withdrawn	US Department of Veterans Affairs	N/A	2007-05-01	This study will determine the effect of ventilatory stimulation on obstructive sleep apnea in selected patients with stroke. We will select a subset of patients with stroke in the prior 3 months who are most likely to have ventilatory instability as a cause of the upper airway obstruction as indicated by the absence of obesity, an abnormal hypocapnic apnea threshold and resolution of obstructive apnea during CO2 administration. Following baseline polysomnography, patients will be randomly assigned to acetazolamide (250 mg hs [at bedtime]) versus placebo for 7 days. Polysomnography will be repeated and then subjects will cross-over therapies for another 7 days followed by a final nocturnal polysomnography.
NCT00108602 ↗	Sleep Apnea: Mechanism and Cerebrovascular Consequences	Withdrawn	VA Office of Research and Development	N/A	2007-05-01	This study will determine the effect of ventilatory stimulation on obstructive sleep apnea in selected patients with stroke. We will select a subset of patients with stroke in the prior 3 months who are most likely to have ventilatory instability as a cause of the upper airway obstruction as indicated by the absence of obesity, an abnormal hypocapnic apnea threshold and resolution of obstructive apnea during CO2 administration. Following baseline polysomnography, patients will be randomly assigned to acetazolamide (250 mg hs [at bedtime]) versus placebo for 7 days. Polysomnography will be repeated and then subjects will cross-over therapies for another 7 days followed by a final nocturnal polysomnography.
NCT00120731 ↗	Effects of Potassium Citrate in Urine of Children With Elevated Calcium in Urine and Kidney Stones	Withdrawn	Children's Mercy Hospital Kansas City	N/A	2005-07-01	High amounts of calcium in the urine (hypercalciuria) can cause development of kidney stones in children. Treatment for these children includes plenty of fluids, a low-salt diet and medications such as potassium citrate. A major advantage of potassium citrate, as compared to hydrochlorothiazide, is its lack of side effects. One problem the researchers and others have observed is that some children continue to form kidney stones despite correction of hypercalciuria with potassium citrate. One possible explanation is that in some individuals potassium citrate therapy results in an excessive elevation of urine pH, a situation that may predispose to calcium phosphate stone formation. In this study, the researchers will study the effects of potassium citrate on urine chemistries and acid-base balance in three groups of children aged 5-17 years: - children who are hypercalciuric stone formers; - healthy children without a history of hypercalciuria or kidney stones. Particular attention will be paid to try to identify those who develop a very high urine pH (>8) and the factors leading to this metabolic reaction. The researchers will try to learn whether it is the child's characteristics, the disease manifestations, the dose of the drug, or a combination of the above which may be the cause of the development of very alkaline urine. Based on the results, the researchers hope to be able to better "tailor" the individual treatment for each child with kidney stones.

Clinical Trial Conditions for ACETAZOLAMIDE

Condition Name

Condition Name for ACETAZOLAMIDE
Intervention	Trials
Obstructive Sleep Apnea	12
Chronic Obstructive Pulmonary Disease	8
Acute Mountain Sickness	8
Altitude Hypoxia	8

Condition MeSH

Condition MeSH for ACETAZOLAMIDE
Intervention	Trials
Altitude Sickness	28
Sleep Apnea Syndromes	21
Sleep Apnea, Obstructive	16
Apnea	14

Clinical Trial Locations for ACETAZOLAMIDE

Trials by Country

Trials by Country for ACETAZOLAMIDE
Location	Trials
United States	123
Kyrgyzstan	18
Belgium	8
Israel	7
Switzerland	6

Trials by US State

Trials by US State for ACETAZOLAMIDE
Location	Trials
California	15
Massachusetts	11
Texas	7
Florida	6
Pennsylvania	6

Clinical Trial Progress for ACETAZOLAMIDE

Clinical Trial Phase

Clinical Trial Phase for ACETAZOLAMIDE
Clinical Trial Phase	Trials
Phase 4	50
Phase 3	14
Phase 2/Phase 3	7

Clinical Trial Status

Clinical Trial Status for ACETAZOLAMIDE
Clinical Trial Phase	Trials
Completed	64
Recruiting	26
Not yet recruiting	16

Clinical Trial Sponsors for ACETAZOLAMIDE

Sponsor Name

Sponsor Name for ACETAZOLAMIDE
Sponsor	Trials
University of Zurich	23
National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov	16
University of California, San Diego	5

Sponsor Type

Sponsor Type for ACETAZOLAMIDE
Sponsor	Trials
Other	203
NIH	16
U.S. Fed	8